AU2018362014A1 - CD38-directed chimeric antigen receptor constructs - Google Patents

CD38-directed chimeric antigen receptor constructs Download PDF

Info

Publication number
AU2018362014A1
AU2018362014A1 AU2018362014A AU2018362014A AU2018362014A1 AU 2018362014 A1 AU2018362014 A1 AU 2018362014A1 AU 2018362014 A AU2018362014 A AU 2018362014A AU 2018362014 A AU2018362014 A AU 2018362014A AU 2018362014 A1 AU2018362014 A1 AU 2018362014A1
Authority
AU
Australia
Prior art keywords
acid sequence
amino acid
car
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018362014A
Other languages
English (en)
Inventor
Qianzhong MA
Yanliang Zhang
Heyue Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AU2018362014A1 publication Critical patent/AU2018362014A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AU2018362014A 2017-11-03 2018-11-02 CD38-directed chimeric antigen receptor constructs Abandoned AU2018362014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581466P 2017-11-03 2017-11-03
US62/581,466 2017-11-03
PCT/IB2018/058642 WO2019087151A1 (en) 2017-11-03 2018-11-02 Cd38-directed chimeric antigen receptor constructs

Publications (1)

Publication Number Publication Date
AU2018362014A1 true AU2018362014A1 (en) 2020-05-28

Family

ID=64277751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018362014A Abandoned AU2018362014A1 (en) 2017-11-03 2018-11-02 CD38-directed chimeric antigen receptor constructs

Country Status (8)

Country Link
US (1) US11760806B2 (https=)
EP (1) EP3704156A1 (https=)
JP (1) JP2021501587A (https=)
KR (1) KR20200076732A (https=)
CN (1) CN111542545A (https=)
AU (1) AU2018362014A1 (https=)
CA (1) CA3080109A1 (https=)
WO (1) WO2019087151A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202008568WA (en) 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
CN112313250B (zh) * 2018-06-20 2024-10-01 索伦托药业有限公司 结合cd38的变体抗体
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
CA3144961A1 (en) * 2019-07-01 2021-01-07 Sorrento Therapeutics, Inc. Heterodimeric antibodies that bind to cd38 and cd3
CN114258401B (zh) * 2019-07-16 2025-08-12 Inserm(法国国家健康医学研究院) 对cd38具有特异性的抗体及其用途
US20220273716A1 (en) * 2019-07-25 2022-09-01 Celularity Inc. Populations of natural killer cells comprising a cd38 chimeric antigen receptor
WO2022081486A1 (en) * 2020-10-12 2022-04-21 Sorrento Therapeutics, Inc. Cd19-directed chimeric antigen receptor constructs
CN113663061A (zh) * 2021-08-04 2021-11-19 上海优卡迪生物医药科技有限公司 Cd38在制备car-t药物中的应用
CN113893338A (zh) * 2021-11-04 2022-01-07 苏州大学附属第一医院 Cd38 car-t细胞在慢性粒细胞白血病急髓变中的应用
EP4612188A2 (en) * 2022-11-02 2025-09-10 Medisix Therapeutics, Inc. Methods and systems for production of engineered t-cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE69334095T2 (de) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CN107531800B (zh) 2014-07-25 2021-08-10 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
CN107002084B (zh) * 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
CN105802975B (zh) * 2014-12-31 2020-04-14 浙江大学 靶向her2阳性肿瘤的细胞制备物及其用途
ES2927119T3 (es) * 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
CN108135937A (zh) * 2015-04-15 2018-06-08 罗杰威廉姆斯医疗中心以普拉斯派克特查特凯尔Rwmc有限责任公司许可 Car-t细胞的肝动脉灌注
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
JP2020508080A (ja) 2017-02-21 2020-03-19 ユーティレックス カンパニー リミテッド Ｈｌａ−ｄｒ ｃａｒ−ｔ組成物ならびにその作製方法および使用方法
SG11202008568WA (en) * 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
CA3107378A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy

Also Published As

Publication number Publication date
CA3080109A1 (en) 2019-05-09
KR20200076732A (ko) 2020-06-29
CN111542545A (zh) 2020-08-14
US11760806B2 (en) 2023-09-19
WO2019087151A1 (en) 2019-05-09
US20190135937A1 (en) 2019-05-09
EP3704156A1 (en) 2020-09-09
JP2021501587A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
US11760806B2 (en) CD-38 directed chimeric antigen receptor constructs
EP3817763B1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
US20210340219A1 (en) Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
US20170281682A1 (en) Chimeric receptors and uses thereof in immune therapy
TW202000691A (zh) 嵌合跨膜蛋白及其用途
US12534507B2 (en) B cell targeted parallel car (pCAR) therapeutic agents
US20210261646A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
US20240082306A1 (en) Novel chimeric antigen receptor and use thereof
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
US12269861B2 (en) Chimeric ILT receptor compositions and methods
US20250297259A1 (en) Engineered immune cell with ciita gene knock-out and use thereof
WO2022232277A1 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
JP2024500985A (ja) 双方向シグナル伝達活性を有するキメラ膜貫通タンパク質
KR20250133399A (ko) 유전자 전달 및 합성 및 면역 수용체의 활성을 제어하기 위한 방법 및 조성물
US20260053924A1 (en) Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
US20240261330A1 (en) CD19-Directed Chimeric Antigen Receptor Constructs
WO2025140265A1 (en) Combination of chimeric antigen receptor and dap10 in cell therapy
WO2022242701A1 (en) Genetically modified gamma-delta t cells and uses thereof
HK40030299A (en) Cd38-directed chimeric antigen receptor constructs
WO2025214498A1 (en) Composition and method of cellular immunotherapy
US12286465B2 (en) Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
EP4731753A2 (en) Gpc3-targeted molecules and uses thereof
WO2026011052A1 (en) Car-t cell therapy for triple negative breast cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application